Prodrugs pp 525-540 | Cite as

Antibody-Directed Enzyme Prodrug Therapy

  • Kenneth D. Bagshawe
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


Antibody-directed enzyme prodrug therapy (ADEPT) was conceived as a means of reducing the toxicity of chemotherapy and improving its efficacy by generating the cytotoxic agent at tumor sites (Figure 1). It was proposed that this could be done by using an antibody directed at a tumor-associated antigen to convey an enzyme to tumor sites and, when the enzyme had cleared from the blood, to give a low toxicity prodrug from which a high toxicity drug would be released by enzymic catalysis within tumors. The active drug would be a small molecule able to diffuse within a tumor and thus overcome the heterogeneity in tumor marker expression that was seen as a potential limitation to conjugates of cytotoxic agents and antibodies. At the outset it was envisaged that the antibodyenzyme complex could be genetically engineered and that the drug generated would have a very short half-life (Bagshawe, 1987).


Cytosine Deaminase Enzyme Prodrug Therapy Radiolabelled Antibody Antibody Direct Enzyme Prodrug Therapy London Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aboagye EO, Artemov D, Senter PD, and Bhujwalla ZM. Intratumoral Conversion of 5-Fluorocytosine to 5-Fluorouracil by Monoclonal Antibody-Cytosine Deaminase Conjugates: Noninvasive Detection of Prodrug Activation by Magnetic Resonance Spectroscopy and Spectroscopic Imaging. Cancer Res 1998; 58:4075–4078PubMedGoogle Scholar
  2. Alexander RP, Beeley NRA, O’Driscoll M, O’Neill FP, Millican RA, Pratt, AJ, and Willenbrock FW. Cephalosporin Nitrogen-Mustare Carbamate Prodrugs for “ADEPT.” Tetrahedron Lett 1991; 32:3269–3272CrossRefGoogle Scholar
  3. Antoniw P, Springer CJ, Bagshawe KD, Searle F, Melton RG, Rogers GT, Burke PJ, and Sherwood RF. Disposition of the Prodrug 4-(bis (2-Chloroethyl) amino) Benzoyl-L-glutamic Acid and its Active Parent Drug in Mice. Br J Cancer 1990; 62:909–914PubMedGoogle Scholar
  4. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F AND Knox RJ. The Bioactivation of 5-(Aziridin-1-Yl)-2,4-Dinitrobenzamide (Cb1954). 1. Purification and Properties of A Nitroreductase Enzyme from Escherichia Coli—A Potential Enzyme for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Biochem Pharmacol 1992; 44:2289–2295PubMedCrossRefGoogle Scholar
  5. Bagshawe KD. Antibody Directed Enzymes Revive Anti-Cancer Prodrugs Concept. Br J Cancer 1987; 56:531–532PubMedGoogle Scholar
  6. Bagshawe KD. The First Bagshawe lecture. Towards Generating Cytotoxic agents at Cancer Sites. Br J Cancer 1989; 60:275–281PubMedGoogle Scholar
  7. Bagshawe KD, and Begent RHJ. First Clinical Experience with ADEPT. Adv Drug Deliv Rev 1996 22: 365–367CrossRefGoogle Scholar
  8. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, and Sherwood RF. A Cytotoxic Agent can be Generated Selectively at Cancer Sites. Br J Cancer 1988; 58:700–703PubMedGoogle Scholar
  9. Bagshawe KD, Sharma SK, Begent RH, Antibody-directed enzyme prodrug therapy (ADEPT) far cancer. Expert Opin Biol Ther, 4: 1777–1789, 2004.PubMedCrossRefGoogle Scholar
  10. Bagshawe KD, Sharma SK, Springer CJ, and Antoniw P. Antibody-Directed enzyme prodrug therapy: A Pilot Scale Clinical Trial. Tumor Targeting 1995; 1:17–29Google Scholar
  11. Begent RH, Searle F, Stanway G, Jewkes RF, Jones BE, Vernon P, and Bagshawe KD. Radioimmunolocalization of Tumors By External Scintigraphy after Administration of 131I Antibody to Human Chorionic Gonadotrophin: Preliminary Communication. J R Soc Med 1980; 73:624–630PubMedGoogle Scholar
  12. Biela BH, Khawli LA, Hu P, and Epstein AL. Chimeric TNT-3/human beta-Glucuronidase Fusion Proteins for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Cancer Biother Radiopharm 2003; 18:339–353PubMedCrossRefGoogle Scholar
  13. Bignami GS, Senter PD, Grothaus PG, Fischer KJ, Humphreys T, and Wallace PM. N-(4’-hydroxyphenylacetyl)palytoxin: A Palytoxin Prodrug that can be Activated by a Monoclonal Antibody-Penicillin G Amidase Conjugate. Cancer Res 1992; 52:5759–5764PubMedGoogle Scholar
  14. Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, Sharma SK, Springer CJ, Mauger AB, and Melton RG. Anti-tumor Effects of an Antibodycarboxypeptidase G2 Conjugate in Combination with Phenol Mustard Prodrugs. Br J Cancer 1995; 72:1083–1088PubMedGoogle Scholar
  15. Bosslet K, Czech J, Lorenz P, Sedlacek HH, Schuermann M, and Seemann G. Molecular and Functional Characterisation of a Fusion Protein Suited for Tumor Specific Prodrug Activation. Br J Cancer 1992; 65:234–238PubMedGoogle Scholar
  16. Cheng TL, Chen BM, Chan LY, Wu PY, Chern JW, and Roffler SR. Poly(ethylene glycol) Modification of beta-Glucuronidase-antibody Conjugates for Solid-Tumor Therapy by Targeted Activation of Glucuronide Prodrugs. Cancer Immunol Immunother 1997; 44:305–315.PubMedCrossRefGoogle Scholar
  17. Cheng TL, Wu PY, Wu MF, Chern JW, and Roffler SR. Accelerated Clearance of Polyethylene Glycol-modified Proteins by Anti-polyethylene Glycol IgM. Bioconjug Chem 1999; 10:520–528PubMedCrossRefGoogle Scholar
  18. Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA, Boxer G, Green A, Winter G, and Cochet O. Phage Libraries for Generation of Clinically Useful Antibodies. Lancet 1994; 343:455–456PubMedCrossRefGoogle Scholar
  19. Deckert PM, Renner C, Cohen LS, Jungbluth A, Ritter G, Bertino JR, Old LJ, and Welt S. A33scFv-cytosine Deaminase: A Recombinant Protein Construct for Antibody-Directed Enzyme-Prodrug Therapy. Br J Cancer 2003; 88:937–939PubMedCrossRefGoogle Scholar
  20. Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy JC, Mondon M, Renoux B, Andrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R, and Bosslet K. Prodrugs of Anthracyclines for use in Antibody-Directed Enzyme Prodrug Therapy. J Med Chem 1998; 41:3572–3581PubMedCrossRefGoogle Scholar
  21. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O’Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, and Begent RH. A Phase I Trial of Antibody Directed Enzyme Prodrug Therapy (ADEPT) in Patients with Advanced Colorectal Carcinoma or Other CEA Producing Tumors. Br J Cancer 2002; 87:600–607PubMedCrossRefGoogle Scholar
  22. Frei E, III, Teicher BA, Holden SA, Cathcart KN, and Wang YY. Preclinical Studies and Clinical Correlation of the Effect of Alkylating Dose. Cancer Res 1988; 48:6417–6423PubMedGoogle Scholar
  23. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van N J, Jr., Estes N, DeSimone P, and Rayburn P. Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning. N Engl J Med 1978; 298:1384–1386PubMedCrossRefGoogle Scholar
  24. Hanessian S, and Wang JG.: Design and Synthesis of A Cephalosporin Carboplatinum Prodrug Activatable by A Beta-Lactamase. Can J Chem—Revue Canadienne de Chimie 1993; 71:896–906CrossRefGoogle Scholar
  25. Heinis C, Alessi P, and Neri D, Engineering a thermostable numan prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Biochemistry, 43: 6293–6303, 2004.PubMedCrossRefGoogle Scholar
  26. Kerr DE, Garrigues US, Wallace PM, Hellstrom KE, Hellstrom I, and Senter PD. Application of Monoclonal Antibodies against Cytosine Deaminase for the In Vivo Clearance of a Cytosine Deaminase Immunoconjugate. Bioconjug Chem 1993; 4:353–357PubMedCrossRefGoogle Scholar
  27. Leu YL, Roffler SR, and Chern JW. Design and Synthesis of Water-soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT). J Med Chem 1999; 42:3623–3628PubMedCrossRefGoogle Scholar
  28. Mach JP, Carrel S, Merenda C, Sordat B, and Cerottini JC. In Vivo Localisation of Radiolabelled Antibodies to Carcinoembryonic Antigen in Human Colon Carcinoma Grafted into Nude Mice. Nature 1974; 248:704–706PubMedCrossRefGoogle Scholar
  29. Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, and Springer CJ. Antibody-Directed Enzyme Prodrug Therapy: Pharmacokinetics and Plasma Levels of Prodrug and Drug in a Phase I Clinical Trial. Cancer Chemother Pharmacol 1997; 40:189–201PubMedCrossRefGoogle Scholar
  30. Mayer A, Sharma SK, Tolner B, Minton NP, Purdy D, Amlot P, Tharakan G, Begent RH, and Chester KA. Modifying an Immunogenic Epitope on a Therapeutic Protein: A Step towards an Improved System for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). Br J Cancer 2004; 90:2402–2410PubMedGoogle Scholar
  31. Medzihradszky KF, Spencer DI, Sharma SK, Bhatia J, Pedley RB, Read DA, Begent RH, and Chester KA. Glycoforms Obtained by Expression in Pichia pastoris Improve Cancer Targeting Potential of a Recombinant Antibody-Enzyme Fusion Protein. Glycobiology 2004; 14:27–37PubMedCrossRefGoogle Scholar
  32. Meyer DL, Jungheim LN, Law KL, Mikolajczyk SD, Shepherd TA, Mackensen DG, Briggs SL, and Starling JJ. Site-specific Prodrug Activation by Antibody-beta-lactamase Conjugates: Regression and Long-term Growth Inhibition of Human Colon Carcinoma Xenograft Models. Cancer Res 1993; 53:3956–3963PubMedGoogle Scholar
  33. Minton NP, Atkinson T, and Sherwood RF. Molecular Cloning of the Pseudomonas Carboxypeptidase G2 Gene and its Expression in Escherichia coli and Pseudomonas putida. J Bacteriol 1983; 156:1222–1227PubMedGoogle Scholar
  34. Monks NR, Blakey DC, Curtin NJ, East SJ, Heuze A, and Newell DR. Induction of Apoptosis by the ADEPT Agent ZD2767: Comparison with the Classical Nitrogen Mustard Chlorambucil and a Monofunctional ZD2767 Analogue. Br J Cancer 2001; 85:764–771PubMedCrossRefGoogle Scholar
  35. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O’Malley D, and Begent RH. Antibody-Directed Enzyme Prodrug Therapy: Efficacy and Mechanism of Action in Colorectal Carcinoma. Clin Cancer Res 2000; 6:765–772PubMedGoogle Scholar
  36. Rader C, Turner JM, Heine A, Shabat D, Sinha SC, Wilson IA, Lerner RA, and Barbas CF. A Humanized Aldolase Antibody for Selective Chemotherapy and Adaptor Immunotherapy. J Mol Biol 2003; 332:889–899PubMedCrossRefGoogle Scholar
  37. Rodrigues ML, Carter P, Wirth C, Mullins S, Lee A, and Blackburn BK. Synthesis and beta-Lactamase-mediated Activation of a Cephalosporin-Taxol Prodrug. Chem Biol 1995; 2:223–227PubMedCrossRefGoogle Scholar
  38. Senter PD and Springer CJ, Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Senter PD and Springer CJ, Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Crug Deliv Rev 53:257–264Google Scholar
  39. Sharma SK, Bagshawe KD, Burke PJ, Boden RW, Rogers GT. Inactivation and Clearance of an Anti-CEA Carboxypeptidase G2 Conjugate in Blood after Localisation in a Xenograft Model. Br J Cancer 1990; 61:659–662PubMedGoogle Scholar
  40. Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT, Boden JA, Antoniw P, Melton RG, and Sherwood RF. Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Three Phase System. Dis Markers 1991; 9:225–231PubMedGoogle Scholar
  41. Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, Melton RG, and Sherwood RF. Galactosylated Antibodies and Antibody-enzyme Conjugates in Antibody-Directed Enzyme Prodrug Therapy. Cancer 1994; 73:1114–1120PubMedCrossRefGoogle Scholar
  42. Sharma, SK, Bhatia J, Pedley RB, Spencer DIR, Minton N., Chester KA, and Begent RHJ 2001; Immunogenicity of Carboxypeptidase G2(CPG2) Enzyme in ADEPT. Br J Cancer 85Suppl. 1:98Google Scholar
  43. Sharma SK, Pedley RB, Bhatia J, Boxer GM, El Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, Begent RH, and Chester KA. Sustained Tumor Regression of Human Colorectal Cancer Xenografts using a Multifunctional Mannosylated Fusion Protein in Antibody-Directed Enzyme Prodrug Therapy. Clin Cancer Res 2005; 11:814–825PubMedGoogle Scholar
  44. Sherwood RF, Melton RG, Alwan SM, and Hughes P. Purification and Properties of Carboxypeptidase G2 from Pseudomonas sp. Strain RS-16. Use of a Novel Triazine Dye Affinity Method. Eur J Biochem 1985; 148:447–453PubMedCrossRefGoogle Scholar
  45. Spencer DI, Robson L, Purdy D, Whitelegg NR, Michael NP, Bhatia J, Sharma SK, Rees AR, Minton NP, Begent RH, and Chester KA. A Strategy for Mapping and Neutralizing Conformational Immunogenic Sites on Protein Therapeutics. Proteomics 2002; 2:271–279PubMedCrossRefGoogle Scholar
  46. Springer C J, Antoniw P, Bagshawe KD, Searle F, Bisset GM, and Jarman M. Novel Prodrugs which are Activated to Cytotoxic Alkylating Agents by Carboxypeptidase G2. J Med Chem 1990; 33:677–681PubMedCrossRefGoogle Scholar
  47. Springer CJ, Niculescu-Duvaz I, and Pedley RB. Novel Prodrugs of Alkylating Agents Derived from 2-Fluoro-and 3-Fluorobenzoic Acids for Antibody-Directed Enzyme Prodrug Therapy. J Med Chem 1994; 37:2361–2370PubMedCrossRefGoogle Scholar
  48. Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC, Melton RG, and Niculescu-Duvaz I. Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). J Med Chem 1995; 38:5051–5065PubMedCrossRefGoogle Scholar
  49. Vrudhula VM, Senter PD, Fischer KJ, and Wallace PM. Prodrugs of Doxorubicin and Melphalan and their Activation by a Monoclonal Antibody-Penicillin-G Amidase Conjugate. J Med Chem 1993; 36:919–923PubMedCrossRefGoogle Scholar
  50. Vrudhula VM, Svensson HP, and Senter PD. Cephalosporin Derivatives of Doxorubicin as Prodrugs for Activation by Monoclonal Antibody-beta-lactamase Conjugates. J Med Chem 1995; 38:1380–1385PubMedCrossRefGoogle Scholar
  51. Wallace PM, and Senter PD. Selective Activation of Anticancer Prodrugs by Monoclonal Antibody-Enzyme Conjugates. Methods Find Exp Clin Pharmacol 1994; 16:505–512PubMedGoogle Scholar
  52. Wallace PM, Macmaster JF, Smith VF, Kerr DE Senter PD, and Cosand WL. Intratumoral Generation of 5-Fluorouracil Mediated by An Antibody Cytosine Deaminase Conjugate in Combination with 5-Fluorocytosine. Cancer Res 1994; 54:2719–2723PubMedGoogle Scholar
  53. Wilman DE. Prodrugs in Cancer Chemotherapy. Biochem Soc Trans 1986; 14:375–382PubMedGoogle Scholar
  54. Wrasidlo W, Gaedicke G, Guy RK, Renaud J, Pitsinos E, Nicolaou KC, Reisfeld RA, and Lode HN. A Novel 2′-(N-methylpyridinium acetate) Prodrug of Paclitaxel Induces Superior Antitumor Responses in Preclinical Cancer Models. Bioconjug Chem 2002; 13:1093–1099PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Kenneth D. Bagshawe
    • 1
  1. 1.Imperial College LondonLondonUK

Personalised recommendations